Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Renal Cell | 75 | 2024 | 3143 | 5.160 |
Why?
|
Kidney Neoplasms | 73 | 2024 | 4262 | 4.390 |
Why?
|
Pyrroles | 32 | 2016 | 1146 | 3.130 |
Why?
|
Indoles | 32 | 2016 | 1839 | 2.750 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 24 | 2023 | 11525 | 1.440 |
Why?
|
Imidazoles | 11 | 2017 | 1206 | 1.050 |
Why?
|
Bone Neoplasms | 14 | 2024 | 2530 | 1.050 |
Why?
|
Angiogenesis Inhibitors | 11 | 2019 | 2038 | 1.040 |
Why?
|
Indazoles | 9 | 2018 | 290 | 1.020 |
Why?
|
Prostatic Neoplasms | 21 | 2024 | 11126 | 0.950 |
Why?
|
Diphosphonates | 5 | 2007 | 623 | 0.930 |
Why?
|
Phenylurea Compounds | 9 | 2021 | 528 | 0.860 |
Why?
|
Antineoplastic Agents | 32 | 2021 | 13693 | 0.820 |
Why?
|
Urinary Bladder Neoplasms | 7 | 2023 | 2249 | 0.750 |
Why?
|
Deoxycytidine | 3 | 2015 | 826 | 0.630 |
Why?
|
Neoplasm Metastasis | 24 | 2022 | 4851 | 0.600 |
Why?
|
Androgen Antagonists | 7 | 2021 | 1377 | 0.570 |
Why?
|
Orchiectomy | 4 | 2013 | 474 | 0.570 |
Why?
|
Carcinoma, Transitional Cell | 4 | 2023 | 808 | 0.560 |
Why?
|
Protein Kinase Inhibitors | 16 | 2023 | 5534 | 0.540 |
Why?
|
Prednisone | 3 | 2014 | 1574 | 0.500 |
Why?
|
Interferon-alpha | 9 | 2014 | 895 | 0.490 |
Why?
|
Pyridines | 9 | 2022 | 2825 | 0.430 |
Why?
|
Disease-Free Survival | 21 | 2017 | 6896 | 0.430 |
Why?
|
Bone Density Conservation Agents | 4 | 2008 | 772 | 0.420 |
Why?
|
Technetium Tc 99m Medronate | 1 | 2012 | 136 | 0.420 |
Why?
|
Anilides | 5 | 2022 | 408 | 0.410 |
Why?
|
Cystectomy | 4 | 2023 | 686 | 0.400 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2012 | 185 | 0.390 |
Why?
|
Dioxoles | 1 | 2011 | 104 | 0.390 |
Why?
|
Tetrahydroisoquinolines | 1 | 2011 | 91 | 0.390 |
Why?
|
Radiation Injuries | 2 | 2016 | 1180 | 0.390 |
Why?
|
Sirolimus | 3 | 2016 | 1565 | 0.390 |
Why?
|
Radium | 2 | 2024 | 65 | 0.380 |
Why?
|
Urogenital Neoplasms | 2 | 2003 | 137 | 0.380 |
Why?
|
Benzenesulfonates | 2 | 2011 | 169 | 0.370 |
Why?
|
RANK Ligand | 1 | 2012 | 326 | 0.360 |
Why?
|
Gastrointestinal Diseases | 2 | 2016 | 1170 | 0.360 |
Why?
|
Cost-Benefit Analysis | 2 | 2020 | 5388 | 0.360 |
Why?
|
Camptothecin | 2 | 2023 | 576 | 0.360 |
Why?
|
Neoplasm Staging | 17 | 2020 | 11031 | 0.340 |
Why?
|
Aged | 57 | 2023 | 163288 | 0.310 |
Why?
|
Male | 80 | 2024 | 350115 | 0.300 |
Why?
|
Molecular Targeted Therapy | 6 | 2019 | 2725 | 0.300 |
Why?
|
Taxoids | 4 | 2014 | 666 | 0.300 |
Why?
|
Nephrectomy | 4 | 2019 | 1050 | 0.290 |
Why?
|
Neovascularization, Pathologic | 3 | 2019 | 2638 | 0.290 |
Why?
|
Humans | 118 | 2024 | 744366 | 0.290 |
Why?
|
Niacinamide | 4 | 2014 | 416 | 0.280 |
Why?
|
Middle Aged | 60 | 2023 | 213390 | 0.280 |
Why?
|
Computer Simulation | 1 | 2020 | 6194 | 0.280 |
Why?
|
Clinical Trials, Phase III as Topic | 5 | 2019 | 841 | 0.270 |
Why?
|
Sarcoma | 2 | 2022 | 1897 | 0.270 |
Why?
|
Lymphocytes | 1 | 2014 | 2617 | 0.270 |
Why?
|
Osteoblastoma | 1 | 2005 | 24 | 0.270 |
Why?
|
Immunotherapy | 3 | 2023 | 4446 | 0.260 |
Why?
|
Kaplan-Meier Estimate | 10 | 2018 | 6539 | 0.260 |
Why?
|
Models, Economic | 2 | 2020 | 712 | 0.260 |
Why?
|
Tourniquets | 1 | 2006 | 110 | 0.260 |
Why?
|
Maximum Tolerated Dose | 4 | 2013 | 892 | 0.260 |
Why?
|
Calcaneus | 1 | 2006 | 138 | 0.250 |
Why?
|
Drug Administration Schedule | 8 | 2016 | 4933 | 0.250 |
Why?
|
Gonadotropin-Releasing Hormone | 2 | 2010 | 1206 | 0.250 |
Why?
|
Antibodies, Monoclonal | 4 | 2023 | 9274 | 0.240 |
Why?
|
Pyrrolidines | 1 | 2006 | 342 | 0.240 |
Why?
|
Quinolines | 4 | 2021 | 732 | 0.240 |
Why?
|
Drug Resistance, Neoplasm | 5 | 2013 | 5172 | 0.230 |
Why?
|
Lung Diseases | 1 | 2014 | 1887 | 0.230 |
Why?
|
Vascular Endothelial Growth Factor A | 5 | 2018 | 3511 | 0.230 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2012 | 2455 | 0.220 |
Why?
|
Paclitaxel | 2 | 2023 | 1708 | 0.220 |
Why?
|
Treatment Outcome | 27 | 2023 | 63107 | 0.220 |
Why?
|
Aged, 80 and over | 25 | 2023 | 57776 | 0.220 |
Why?
|
Treatment Failure | 4 | 2012 | 2618 | 0.210 |
Why?
|
Prostate-Specific Antigen | 6 | 2014 | 2494 | 0.210 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2008 | 1524 | 0.210 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2021 | 10943 | 0.200 |
Why?
|
Testicular Neoplasms | 3 | 2015 | 806 | 0.200 |
Why?
|
Prognosis | 14 | 2019 | 29060 | 0.200 |
Why?
|
Neutrophils | 1 | 2014 | 3721 | 0.200 |
Why?
|
Alkaline Phosphatase | 3 | 2014 | 867 | 0.200 |
Why?
|
Disease Progression | 10 | 2014 | 13286 | 0.190 |
Why?
|
Combined Modality Therapy | 9 | 2019 | 8642 | 0.190 |
Why?
|
Antineoplastic Protocols | 1 | 2020 | 50 | 0.180 |
Why?
|
Osteoclasts | 1 | 2004 | 729 | 0.180 |
Why?
|
Urethra | 2 | 2016 | 408 | 0.170 |
Why?
|
Fatigue | 3 | 2015 | 1531 | 0.160 |
Why?
|
Medical Oncology | 3 | 2022 | 2267 | 0.160 |
Why?
|
Female | 46 | 2023 | 380193 | 0.150 |
Why?
|
Proportional Hazards Models | 8 | 2018 | 12356 | 0.150 |
Why?
|
Survival Analysis | 7 | 2021 | 10252 | 0.150 |
Why?
|
Hematology | 1 | 2021 | 221 | 0.150 |
Why?
|
Drug Delivery Systems | 1 | 2009 | 2219 | 0.150 |
Why?
|
Vascular Endothelial Growth Factor Receptor-3 | 3 | 2013 | 118 | 0.150 |
Why?
|
Osteoporosis | 1 | 2007 | 1579 | 0.150 |
Why?
|
Adult | 30 | 2023 | 214052 | 0.140 |
Why?
|
Receptors, Nerve Growth Factor | 2 | 1996 | 200 | 0.140 |
Why?
|
Gingival Neoplasms | 1 | 2016 | 22 | 0.140 |
Why?
|
Seminoma | 2 | 2015 | 139 | 0.140 |
Why?
|
Immunoconjugates | 1 | 2023 | 901 | 0.140 |
Why?
|
Bone Remodeling | 3 | 2018 | 575 | 0.140 |
Why?
|
Interleukin-7 | 1 | 1996 | 142 | 0.140 |
Why?
|
Macrophage Colony-Stimulating Factor | 1 | 1996 | 193 | 0.140 |
Why?
|
Finger Phalanges | 1 | 2016 | 38 | 0.130 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2016 | 2110 | 0.130 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1115 | 0.130 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 5 | 2017 | 664 | 0.130 |
Why?
|
Tissue Distribution | 1 | 2019 | 2327 | 0.130 |
Why?
|
Drug Synergism | 1 | 2019 | 1794 | 0.130 |
Why?
|
Gossypol | 1 | 2014 | 23 | 0.130 |
Why?
|
Radiography | 4 | 2014 | 7023 | 0.130 |
Why?
|
Radionuclide Imaging | 2 | 2012 | 2031 | 0.120 |
Why?
|
Steroid 17-alpha-Hydroxylase | 1 | 2014 | 98 | 0.120 |
Why?
|
Asthenia | 1 | 2013 | 16 | 0.120 |
Why?
|
Calcium Channel Blockers | 1 | 1997 | 692 | 0.120 |
Why?
|
Salvage Therapy | 3 | 2012 | 1275 | 0.120 |
Why?
|
Glomerular Filtration Rate | 1 | 2021 | 2166 | 0.120 |
Why?
|
Catheter Ablation | 2 | 2006 | 2758 | 0.120 |
Why?
|
Naphthalenes | 1 | 2014 | 194 | 0.110 |
Why?
|
Neoplasm Invasiveness | 3 | 2017 | 3616 | 0.110 |
Why?
|
Quality-Adjusted Life Years | 1 | 2020 | 1683 | 0.110 |
Why?
|
Neoplasms | 3 | 2021 | 21696 | 0.110 |
Why?
|
Clinical Trials as Topic | 7 | 2011 | 7914 | 0.110 |
Why?
|
Bone and Bones | 3 | 2012 | 2576 | 0.110 |
Why?
|
Scalp | 1 | 2016 | 380 | 0.110 |
Why?
|
Survival Rate | 7 | 2019 | 12788 | 0.110 |
Why?
|
Clinical Protocols | 1 | 2019 | 1461 | 0.110 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2014 | 424 | 0.110 |
Why?
|
Muscle, Smooth | 1 | 2016 | 934 | 0.110 |
Why?
|
Phosphorylcholine | 1 | 2012 | 162 | 0.100 |
Why?
|
Receptor Cross-Talk | 1 | 2012 | 119 | 0.100 |
Why?
|
Retrospective Studies | 14 | 2023 | 77460 | 0.100 |
Why?
|
Lymphocyte Count | 1 | 2014 | 793 | 0.100 |
Why?
|
Perioperative Care | 1 | 2019 | 1002 | 0.100 |
Why?
|
Lymphopenia | 1 | 2013 | 285 | 0.100 |
Why?
|
Administration, Oral | 6 | 2015 | 3914 | 0.100 |
Why?
|
Interleukin-8 | 1 | 2013 | 690 | 0.090 |
Why?
|
Neoplasms, Hormone-Dependent | 2 | 2003 | 415 | 0.090 |
Why?
|
Neutropenia | 1 | 2015 | 895 | 0.090 |
Why?
|
Time Factors | 11 | 2017 | 40075 | 0.090 |
Why?
|
Neurons | 4 | 1996 | 9340 | 0.090 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6489 | 0.090 |
Why?
|
Placebos | 1 | 2014 | 1676 | 0.090 |
Why?
|
Receptors, Platelet-Derived Growth Factor | 2 | 2007 | 180 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 1968 | 0.080 |
Why?
|
Phthalazines | 2 | 2008 | 363 | 0.080 |
Why?
|
Muscles | 2 | 2023 | 1614 | 0.080 |
Why?
|
Watchful Waiting | 1 | 2012 | 492 | 0.080 |
Why?
|
Hemoglobins | 1 | 2014 | 1532 | 0.080 |
Why?
|
Quality of Life | 7 | 2014 | 12802 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2019 | 9955 | 0.080 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2011 | 627 | 0.070 |
Why?
|
Nomograms | 1 | 2008 | 228 | 0.070 |
Why?
|
Fractures, Bone | 2 | 2010 | 1947 | 0.070 |
Why?
|
Myocardial Ischemia | 1 | 1997 | 2148 | 0.070 |
Why?
|
Referral and Consultation | 3 | 2014 | 3531 | 0.070 |
Why?
|
Interdisciplinary Communication | 1 | 2012 | 950 | 0.070 |
Why?
|
Hypertension | 2 | 2015 | 8479 | 0.070 |
Why?
|
Early Detection of Cancer | 1 | 2020 | 3086 | 0.070 |
Why?
|
Patient Care Team | 2 | 2020 | 2531 | 0.070 |
Why?
|
DNA Methylation | 1 | 2020 | 4285 | 0.070 |
Why?
|
Drug Discovery | 1 | 2014 | 1058 | 0.070 |
Why?
|
Urologic Diseases | 1 | 2008 | 244 | 0.070 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2007 | 772 | 0.070 |
Why?
|
Tumor Suppressor Proteins | 1 | 2016 | 2850 | 0.070 |
Why?
|
Carcinoma | 1 | 2017 | 2375 | 0.060 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2008 | 360 | 0.060 |
Why?
|
Receptors, Death Domain | 1 | 2024 | 32 | 0.060 |
Why?
|
Anemia | 1 | 2013 | 1503 | 0.060 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2009 | 501 | 0.060 |
Why?
|
Disease Management | 3 | 2017 | 2460 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2012 | 2504 | 0.060 |
Why?
|
Fatal Outcome | 1 | 2008 | 1851 | 0.060 |
Why?
|
Adenocarcinoma | 2 | 2012 | 6364 | 0.060 |
Why?
|
Guideline Adherence | 1 | 2013 | 2265 | 0.060 |
Why?
|
Boston | 3 | 2017 | 9312 | 0.050 |
Why?
|
Cohort Studies | 6 | 2016 | 40559 | 0.050 |
Why?
|
Gadolinium DTPA | 1 | 2006 | 836 | 0.050 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2008 | 740 | 0.050 |
Why?
|
Hydronephrosis | 1 | 2004 | 269 | 0.050 |
Why?
|
Retreatment | 2 | 2017 | 610 | 0.050 |
Why?
|
Models, Biological | 1 | 2019 | 9584 | 0.050 |
Why?
|
Pyrimidines | 3 | 2022 | 2943 | 0.050 |
Why?
|
Comorbidity | 2 | 2014 | 10388 | 0.050 |
Why?
|
Edema | 1 | 2006 | 789 | 0.050 |
Why?
|
Infusions, Intravenous | 1 | 2007 | 2274 | 0.050 |
Why?
|
Head and Neck Neoplasms | 1 | 2016 | 2736 | 0.050 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2004 | 546 | 0.050 |
Why?
|
Benzoxazoles | 1 | 2022 | 77 | 0.050 |
Why?
|
Liver Neoplasms | 3 | 2007 | 4253 | 0.050 |
Why?
|
Collagen Type I | 1 | 2004 | 592 | 0.050 |
Why?
|
Lung Neoplasms | 5 | 2008 | 13104 | 0.050 |
Why?
|
Surge Capacity | 1 | 2020 | 42 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 3 | 2012 | 20130 | 0.050 |
Why?
|
Tumor Burden | 2 | 2017 | 1915 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 4 | 2008 | 35425 | 0.040 |
Why?
|
Interleukin-6 | 2 | 2024 | 3203 | 0.040 |
Why?
|
Double-Blind Method | 1 | 2013 | 12025 | 0.040 |
Why?
|
Brain | 2 | 1996 | 26388 | 0.040 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2021 | 290 | 0.040 |
Why?
|
Prostatectomy | 1 | 2008 | 1890 | 0.040 |
Why?
|
Magnetic Resonance Angiography | 1 | 2006 | 1443 | 0.040 |
Why?
|
Bone Density | 2 | 2014 | 3468 | 0.040 |
Why?
|
Cytokines | 3 | 2024 | 7323 | 0.040 |
Why?
|
Urologic Neoplasms | 1 | 2003 | 318 | 0.040 |
Why?
|
Tyrosine | 1 | 2023 | 1462 | 0.040 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2003 | 484 | 0.040 |
Why?
|
Rats, Sprague-Dawley | 4 | 1997 | 8300 | 0.040 |
Why?
|
Dyspnea | 1 | 2006 | 1303 | 0.040 |
Why?
|
Osteoblasts | 1 | 2004 | 1166 | 0.040 |
Why?
|
Aurintricarboxylic Acid | 1 | 1997 | 11 | 0.040 |
Why?
|
Morbidity | 1 | 2004 | 1768 | 0.040 |
Why?
|
Fluorouracil | 1 | 2003 | 1619 | 0.040 |
Why?
|
Remission Induction | 1 | 2003 | 2385 | 0.040 |
Why?
|
Genes, fms | 1 | 1996 | 6 | 0.040 |
Why?
|
Cisplatin | 1 | 2023 | 1662 | 0.040 |
Why?
|
Receptors, Interleukin-7 | 1 | 1996 | 38 | 0.040 |
Why?
|
Sulfonamides | 2 | 2018 | 1940 | 0.040 |
Why?
|
Patient Selection | 2 | 2012 | 4216 | 0.040 |
Why?
|
Osteopetrosis | 1 | 1996 | 43 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-fyn | 1 | 1996 | 116 | 0.040 |
Why?
|
Radioisotopes | 1 | 2018 | 500 | 0.040 |
Why?
|
Bicuculline | 1 | 1996 | 99 | 0.040 |
Why?
|
Urinary Bladder | 1 | 2023 | 1173 | 0.040 |
Why?
|
Receptor, Macrophage Colony-Stimulating Factor | 1 | 1996 | 87 | 0.040 |
Why?
|
Erythropoietin | 1 | 2021 | 726 | 0.040 |
Why?
|
GABA Antagonists | 1 | 1996 | 128 | 0.040 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 1997 | 187 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2016 | 5692 | 0.030 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2017 | 187 | 0.030 |
Why?
|
Propensity Score | 1 | 2023 | 1781 | 0.030 |
Why?
|
Multivariate Analysis | 3 | 2017 | 12244 | 0.030 |
Why?
|
Follow-Up Studies | 6 | 2019 | 39052 | 0.030 |
Why?
|
Androgens | 1 | 2003 | 1281 | 0.030 |
Why?
|
Diagnosis, Differential | 2 | 2008 | 12961 | 0.030 |
Why?
|
Cholesterol | 1 | 2004 | 2919 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2307 | 0.030 |
Why?
|
Collagen | 1 | 2004 | 2688 | 0.030 |
Why?
|
Receptors, Interleukin | 1 | 1996 | 245 | 0.030 |
Why?
|
Delivery of Health Care | 1 | 2013 | 5321 | 0.030 |
Why?
|
Genes, myc | 1 | 1996 | 399 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2002 | 2879 | 0.030 |
Why?
|
Image Enhancement | 1 | 2006 | 2921 | 0.030 |
Why?
|
Contrast Media | 2 | 2006 | 5300 | 0.030 |
Why?
|
Apoptosis | 3 | 1997 | 9724 | 0.030 |
Why?
|
Risk Factors | 7 | 2017 | 72296 | 0.030 |
Why?
|
Neoplasm Proteins | 1 | 2007 | 3707 | 0.030 |
Why?
|
Mutation | 2 | 2016 | 29786 | 0.030 |
Why?
|
Neurites | 1 | 1996 | 388 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2004 | 3759 | 0.030 |
Why?
|
Rats | 5 | 1997 | 24252 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2003 | 4777 | 0.030 |
Why?
|
Superior Cervical Ganglion | 1 | 1993 | 33 | 0.030 |
Why?
|
Inflammation | 1 | 2014 | 10637 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2024 | 2645 | 0.030 |
Why?
|
Risk Assessment | 5 | 2014 | 23336 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2016 | 629 | 0.030 |
Why?
|
Electrophysiology | 1 | 1996 | 1308 | 0.030 |
Why?
|
Cells, Cultured | 4 | 1996 | 19233 | 0.030 |
Why?
|
Physician's Role | 1 | 2020 | 943 | 0.030 |
Why?
|
Regional Blood Flow | 2 | 2008 | 1525 | 0.030 |
Why?
|
Maxilla | 1 | 2016 | 471 | 0.030 |
Why?
|
Mice, Mutant Strains | 1 | 1996 | 1865 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 2015 | 1420 | 0.030 |
Why?
|
Animals | 7 | 2024 | 168768 | 0.030 |
Why?
|
Signal Transduction | 2 | 2016 | 23404 | 0.030 |
Why?
|
Hospitals, General | 1 | 2017 | 749 | 0.030 |
Why?
|
Growth Inhibitors | 1 | 1993 | 385 | 0.030 |
Why?
|
Fellowships and Scholarships | 1 | 2021 | 1078 | 0.030 |
Why?
|
Cell Hypoxia | 1 | 1994 | 675 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1782 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2013 | 426 | 0.030 |
Why?
|
Peptides | 1 | 2004 | 4410 | 0.030 |
Why?
|
RNA Splicing | 1 | 1996 | 908 | 0.030 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3590 | 0.020 |
Why?
|
Models, Statistical | 2 | 2018 | 5101 | 0.020 |
Why?
|
Pyrazoles | 1 | 2022 | 1972 | 0.020 |
Why?
|
RNA, Messenger | 2 | 1996 | 13035 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2014 | 601 | 0.020 |
Why?
|
Kidney | 1 | 2006 | 7184 | 0.020 |
Why?
|
Marital Status | 1 | 2012 | 437 | 0.020 |
Why?
|
Nerve Growth Factors | 1 | 1993 | 574 | 0.020 |
Why?
|
Evoked Potentials | 1 | 1996 | 1056 | 0.020 |
Why?
|
Lymphokines | 1 | 1993 | 949 | 0.020 |
Why?
|
Odds Ratio | 2 | 2014 | 9849 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2016 | 1758 | 0.020 |
Why?
|
Algorithms | 1 | 2010 | 13882 | 0.020 |
Why?
|
Young Adult | 4 | 2018 | 56429 | 0.020 |
Why?
|
Cell Survival | 2 | 1996 | 5882 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2014 | 1677 | 0.020 |
Why?
|
Angiogenic Proteins | 1 | 2009 | 104 | 0.020 |
Why?
|
Ischemia | 1 | 1997 | 1907 | 0.020 |
Why?
|
United States | 4 | 2021 | 69872 | 0.020 |
Why?
|
Lymphatic Metastasis | 2 | 2007 | 2924 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor C | 1 | 2008 | 126 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2019 | 2727 | 0.020 |
Why?
|
Base Sequence | 2 | 1996 | 12797 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3595 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2009 | 667 | 0.020 |
Why?
|
Kidney Transplantation | 1 | 2003 | 4251 | 0.020 |
Why?
|
Geography | 1 | 2010 | 669 | 0.020 |
Why?
|
Genetic Testing | 1 | 2020 | 3444 | 0.020 |
Why?
|
Pregnancy Proteins | 1 | 2008 | 229 | 0.020 |
Why?
|
Up-Regulation | 1 | 1996 | 4222 | 0.020 |
Why?
|
Feasibility Studies | 2 | 2008 | 5077 | 0.020 |
Why?
|
Hemodynamics | 1 | 1997 | 4196 | 0.020 |
Why?
|
Retina | 1 | 1997 | 2616 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2015 | 3773 | 0.020 |
Why?
|
Regression Analysis | 1 | 2016 | 6459 | 0.020 |
Why?
|
Survivors | 1 | 2017 | 2291 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 1996 | 18111 | 0.020 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 934 | 0.020 |
Why?
|
Antigens, CD | 1 | 1996 | 4026 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2008 | 15297 | 0.020 |
Why?
|
Solubility | 1 | 2007 | 1088 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2013 | 941 | 0.020 |
Why?
|
Recurrence | 1 | 2017 | 8340 | 0.020 |
Why?
|
Phosphorylation | 1 | 1996 | 8436 | 0.020 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2009 | 624 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2024 | 18034 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 547 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 1996 | 4554 | 0.010 |
Why?
|
Permeability | 1 | 2006 | 738 | 0.010 |
Why?
|
Single-Blind Method | 1 | 2007 | 1590 | 0.010 |
Why?
|
Probability | 1 | 2009 | 2506 | 0.010 |
Why?
|
Spin Labels | 1 | 2005 | 332 | 0.010 |
Why?
|
Mice | 2 | 2024 | 81201 | 0.010 |
Why?
|
Calibration | 1 | 2006 | 816 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2009 | 2971 | 0.010 |
Why?
|
Microscopy, Electron | 2 | 1997 | 2646 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2009 | 3480 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 1993 | 4463 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8385 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2007 | 1904 | 0.010 |
Why?
|
Biopsy | 1 | 2012 | 6755 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2007 | 2715 | 0.010 |
Why?
|
Protons | 1 | 2004 | 1127 | 0.010 |
Why?
|
Cell Differentiation | 1 | 1996 | 11486 | 0.010 |
Why?
|
Aorta | 1 | 2006 | 2062 | 0.010 |
Why?
|
Respiration | 1 | 2004 | 1653 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2015 | 7282 | 0.010 |
Why?
|
Phantoms, Imaging | 1 | 2006 | 2480 | 0.010 |
Why?
|
Fenfluramine | 1 | 1997 | 59 | 0.010 |
Why?
|
DNA Fragmentation | 1 | 1997 | 242 | 0.010 |
Why?
|
Logistic Models | 1 | 2012 | 13409 | 0.010 |
Why?
|
Cyclobutanes | 1 | 1997 | 59 | 0.010 |
Why?
|
Appetite Depressants | 1 | 1997 | 110 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2007 | 3799 | 0.010 |
Why?
|
Health Status | 1 | 2010 | 4034 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15078 | 0.010 |
Why?
|
Adrenergic beta-Agonists | 1 | 1997 | 346 | 0.010 |
Why?
|
Physicians | 1 | 2014 | 4567 | 0.010 |
Why?
|
Age Factors | 1 | 2012 | 18373 | 0.010 |
Why?
|
Obesity | 1 | 1997 | 12746 | 0.010 |
Why?
|
Pregnancy | 1 | 1996 | 29144 | 0.010 |
Why?
|
Leukemia Inhibitory Factor | 1 | 1993 | 61 | 0.010 |
Why?
|
Research Design | 1 | 2010 | 5984 | 0.010 |
Why?
|
Ciliary Neurotrophic Factor | 1 | 1993 | 77 | 0.010 |
Why?
|
Ultrasonography | 1 | 2006 | 5984 | 0.010 |
Why?
|
Fluoxetine | 1 | 1997 | 749 | 0.010 |
Why?
|
Genetic Markers | 1 | 1997 | 2634 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2012 | 8861 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2007 | 7882 | 0.010 |
Why?
|
Animals, Newborn | 1 | 1993 | 2726 | 0.000 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2005 | 8949 | 0.000 |
Why?
|
Energy Metabolism | 1 | 1997 | 2897 | 0.000 |
Why?
|
Kinetics | 1 | 1993 | 6476 | 0.000 |
Why?
|
Analysis of Variance | 1 | 1993 | 6366 | 0.000 |
Why?
|
Prospective Studies | 1 | 2008 | 53290 | 0.000 |
Why?
|
DNA Damage | 1 | 1993 | 2432 | 0.000 |
Why?
|
Chromatin | 1 | 1994 | 2933 | 0.000 |
Why?
|
DNA | 1 | 1994 | 7294 | 0.000 |
Why?
|
Calcium | 1 | 1993 | 5755 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 1997 | 15160 | 0.000 |
Why?
|